目的 探討杞黃降糖膠囊聯(lián)合利拉魯肽注射液治療血糖控制不佳的2型糖尿病的臨床療效。方法 選取新鄉(xiāng)市中心醫(yī)院2021年11月至2022年5月收治的85例2型糖尿病患者。采用隨機(jī)數(shù)字表法將85例2型糖尿病患者分為對照組（42例）和治療組（43例）。對照組皮下注射利拉魯肽注射液，起始0.6 mg/次，1次/d，１周后無不良反應(yīng)則加量至1.2 mg/次。在對照組的基礎(chǔ)上，治療組口服杞黃降糖膠囊，6粒/次，3次/d。兩組患者均治療12周。觀察兩組的臨床療效，比較兩組生活質(zhì)量、血糖指標(biāo)和胰島素相關(guān)指標(biāo)。結(jié)果 治療后，對照組的總有效率為73.81%，治療組的總有效率為93.02%，治療組的總有效率高于對照組（P＜0.05）。治療后，兩組的生存質(zhì)量量表（DMQLS）各維度評分均下降（P＜0.05），且治療組DMQLS各維度評分均低于對照組（P＜0.05）。治療后，兩組空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血紅蛋白（HbAlc）均下降（P＜0.05），且治療組FBG、2 h PG、HbAlc均低于對照組（P＜0.05）。治療后，兩組胰島素（FINS）、穩(wěn)態(tài)模型胰島β細(xì)胞分泌指數(shù)（HOMA-β）、穩(wěn)態(tài)模型胰島素抵抗指數(shù)（HOMA-IR）均升高（P＜0.05），且治療組FINS、HOMA-β、HOMA-IR均高于對照組（P＜0.05）。結(jié)論 杞黃降糖膠囊聯(lián)合利拉魯肽注射液治療血糖控制不佳的2型糖尿病可促進(jìn)患者生活質(zhì)量提升，有效控制血糖，改善胰島素水平。

Objective To investigate the clinical efficacy of Qihuang Jiangtang Capsules combined with Liraglutide Injection in treatment of type 2 diabetes mellitus with poor glycemic control. Methods Patients (85 cases) with type 2 diabetes mellitus with poor glycemic control in Xinxiang Central Hospital from November 2021 to December 2022 were divided into the control group (42 cases) and the treatment group (43 cases) according to random number tablet method. Patients in the control group were sc administered with Liraglutide Injection, starting at 0.6 mg/time, once daily, if there were no adverse reactions after one week, the dosage was increased to 1.2 mg/time. Patients in the treatment group were po administered with Qihuang Jiangtang Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and the Quality of life, blood glucose indicators, and insulin related indicators in two groups were compared. Results After treatment, the total effective rate of the control group was 73.81%, while the total effective rate of the treatment group was 93.02%. The clinical total effective rate of the treatment group was higher than that of the control group (P＜0.05). After treatment, the scores of all dimensions of DMQLS in two groups decreased (P＜ 0.05), and the scores of all dimensions of DMQLS in the treatment group were lower than those in the control group (P＜0.05). After treatment, FBG, 2 h PG, and HbAlc in two groups were decreased (P＜0.05), and FBG, 2 h PG, and HbAlc in the treatment group were lower than those in the control group (P＜0.05). After treatment, FINS, HOMA-β, and HOMA-IR in two groups increased (P＜0.05), and FINS, HOMA-β, and HOMA-IR in the treatment group were higher than those in the control group (P＜0.05). Conclusion Qihuang Jiangtang Capsules combined with Liraglutide Injection in treatment of type 2 diabetes mellitus with poor glycemic control, which can improve the quality of life of patients, effectively control blood sugar and improve insulin levels.

R977

河南省醫(yī)學(xué)科技攻關(guān)計劃項(xiàng)目（LHGJ20191331）；新鄉(xiāng)市神經(jīng)重大疾病診療與轉(zhuǎn)化重點(diǎn)實(shí)驗(yàn)室項(xiàng)目